Genomic predictors of treatment response in prostate cancer
4 Jul 2017
Genomic predictors of treatment response in prostate cancer
Synthetic lethality as a basis to select drug combinations
Patient-specific peptide vaccines
Proteogenomics in cancer research
Novel models to personalise cancer therapeutics
The Umberto Veronesi Milan Breast Cancer Conference
Front-line combinations in multiple myeloma: Highlights from EHA 2017
Latest maintenance strategies in multiple myeloma
Lenalidomide with CD19 antibodies in L-MIND
Denosumab or zoledronic acid for bone disease in multiple myeloma
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM
Delayed infection exposure as a trigger for childhood ALL